To further evaluate the relationship between HER2 binding kinetics and the antitumor potency of HCT-mono-mIL12, we repeated the in vivo study in BALB/c mice bearing a single-flank tumor of CT26-HER2/neu cells (Figure 3A). Here, ERBB2 is linked to neoplasm.